J&J Weighs Topamax Controlled-Release Formulation After Dropping Obesity Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Controlled-release topiramate was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release formulation. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says; the formulation remains under evaluation for other indications.
You may also be interested in...
Obesity Market Could Add Two New Therapies In The Near Term, Pfizer Says
The obesity drug market could potentially see two new entrants in the near term, Pfizer VP-U.S. Cardiovascular Medical Group Gary Palmer, MD, said Dec. 1 at the Health Care Research & Innovations Congress in Washington, D.C
Obesity Market Could Add Two New Therapies In The Near Term, Pfizer Says
The obesity drug market could potentially see two new entrants in the near term, Pfizer VP-U.S. Cardiovascular Medical Group Gary Palmer, MD, said Dec. 1 at the Health Care Research & Innovations Congress in Washington, D.C
Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad
Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.